CalAmp (CAMP)

Take Impact Assessment
Overall impact
D (36)

Commentary

CalAmp is a below-average overall performer. With a 'D' rating of 35.6 for overall impact (bottom 25% of all companies), CalAmp ranks 26th out of 28 industry peers, behind PC Tel, Spok, Sk Telecom and 22 others, and ahead of EOLO and Corelogic. On top material causes for CalAmp's industry (Telecommunications), CalAmp performs poorly in No Violence Against Women (28.7 score), Arts and Culture Access (30.5), Fair Labor Practices (19.5) and 12 other causes where it received a 'D' or 'F' score. CalAmp did not receive an 'A' rating on any cause.
... read full commentary
Less
Screens
Advertising
Alcohol
Alcohol - responsible marketing
Animal treatment
Anti-abortion support
Anti-Israel
Anti-personnel mines
Arctic drilling
Banned pesticides and chemicals
Biological and chemical weapons
Cannabis
Carbon emissions intensity
Child safety
Cluster munitions
Coal
Contraceptives
Controversial weapons
Deforestation - financing
Deforestation - supply chain
Depleted uranium
Discrimination controversies
Electrical utility
Endangered wildlife
Environmental controversies
EU sanctions list
Factory farming
Fast food
Firearms
Food commodity derivatives
For-profit health care
Fossil fuel
Fur
Gambling
Genetic engineering
Health-related controversies
Human rights controversies
Human trafficking
ILO Conventions
Interest-based products
Interest-bearing debt
Interest-bearing securities
Iran
Land use and biodiversity
Military contracting
Misleading communication
Modern slavery
Music
Myanmar
Non-sustainable palm oil
Norges Bank exclusion list
Northern Ireland (Macbride)
North Korea
No SBTI commitment
Nuclear
OECD Guidelines
Oil and gas
Opioid controversies
Oppressive governments
Palestinian human rights
Pharma controversies
Pork
Pornography
Predatory lending
Prison involvement
Privacy breaches
Pro-life
Russia
Single-use plastic
Stem cell research
Sudan
Sugar
Syria
Tar sands
Thermal coal
Tobacco
Tobacco - GICS
UK sanctions list
Undermining US elections
UN Global Compact
UN Guiding Principles
US OFAC sanctions list
Weapons
Impact
Cause CAMP
Peer rank
Overall impact

Log in to view this information

Screens
Advertising
Alcohol
Alcohol - responsible marketing
Animal treatment
Anti-abortion support
Anti-Israel
Anti-personnel mines
Arctic drilling
Banned pesticides and chemicals
Biological and chemical weapons
Cannabis
Carbon emissions intensity
Child safety
Cluster munitions
Coal
Contraceptives
Controversial weapons
Deforestation - financing
Deforestation - supply chain
Depleted uranium
Discrimination controversies
Electrical utility
Endangered wildlife
Environmental controversies
EU sanctions list
Factory farming
Fast food
Firearms
Food commodity derivatives
For-profit health care
Fossil fuel
Fur
Gambling
Genetic engineering
Health-related controversies
Human rights controversies
Human trafficking
ILO Conventions
Interest-based products
Interest-bearing debt
Interest-bearing securities
Iran
Land use and biodiversity
Military contracting
Misleading communication
Modern slavery
Music
Myanmar
Non-sustainable palm oil
Norges Bank exclusion list
Northern Ireland (Macbride)
North Korea
No SBTI commitment
Nuclear
OECD Guidelines
Oil and gas
Opioid controversies
Oppressive governments
Palestinian human rights
Pharma controversies
Pork
Pornography
Predatory lending
Prison involvement
Privacy breaches
Pro-life
Russia
Single-use plastic
Stem cell research
Sudan
Sugar
Syria
Tar sands
Thermal coal
Tobacco
Tobacco - GICS
UK sanctions list
Undermining US elections
UN Global Compact
UN Guiding Principles
US OFAC sanctions list
Weapons
Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
48
Sector
Communication Services
Industry
Wireless Telecommunication Services
Sub-industry
Wireless Telecommunication Services
SASB industry
Telecommunication Services
Headquarters
Ma, United States
Share classes
CAMP
More info
https://www.camp4tx.com
Description
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001, which is in a Phase 1 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Material causes
Ethos considers the following causes material for CalAmp, based on its industry sub-industry Wireless Telecommunication Services. Learn more about material causes in our methodology overview.
Accountable institutions
Build accountable and inclusive institutions at all levels
Arts and culture access
Support arts and culture creation, preservation, and access everywhere
Conflict-free mineral production
Reduce violence in the production of minerals
Decent, safe work opportunities
Promote full and productive employment for all, in safe work environments
Disaster readiness and effective aid
Be prepared for natural disasters and provide effective aid when disasters happen
Equal pay and opportunity
Achieve equal pay and opportunity for women everywhere
Fair labor practices
Ensure fair and humane labor practices everywhere
Free, secure flow of information
Ensure a free and open flow of information, with secure personal data and privacy
Improved mental health
Support awareness and access to mental health support for all
LGBTQ equality
Ensure equal rights for all lesbian, lesbian, gay, bisexual, transgender and queer people
No poverty
End poverty in all its forms everywhere
No violence against women
End violence against women and all trafficking
Quality lifelong education
Ensure access to quality secondary education and lifelong learning opportunities for all
Quality primary education
Provide inclusive and quality education for all children
Racial justice and civil rights
Eliminate racism and ensure justice for all
Reduced green house gas emissions
Continually reduce green house gas emissions and other pollutants
Reduced inequality
Reduce inequality within and among countries
Reduced waste
Reduce waste and support re-usable materials
Safety from violent conflict
Promote peace and security for all, including reducing violent conflict
Sustainable use of natural resources
Ensure sustainable use of natural resources
Technology innovation
Foster technology innovation that supports sustainable economic development
Terrestrial biodiversity
Protect biodiversity and wildlife habitats on land, preserve forests and combat land degradation
Peace and justice
Promote peaceful and inclusive societies, provide access to justice for all
Quality education
Ensure inclusive and equitable quality education and promote lifelong learning opportunities for all
Sustainable resource use
Ensure sustainable consumption and production patterns
Inclusive economies
Create inclusive economies with no poverty, decent work for all, and affordable living conditions
Climate action
Take urgent action to combat climate change and its impacts
Gender equality
Achieve gender equality and empower all women and girls
Innovation
Innovate to foster economic growth and human development
Health and well-being
Ensure healthy lives and promote well-being for all at all ages
Life on earth
Protect biodiversity and ensure sustainable use of ecosystems

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.
OK
OK, I agree
No thanks